Preud’homme, Gregoire
Duarte, Kevin
Dalleau, Kevin
Lacomblez, Claire
Bresso, Emmanuel
Smaïl-Tabbone, Malika
Couceiro, Miguel
Devignes, Marie-Dominique
Kobayashi, Masatake
Huttin, Olivier
Ferreira, João Pedro
Zannad, Faiez
Rossignol, Patrick
Girerd, Nicolas
Funding for this research was provided by:
No funding
Article History
Received: 28 September 2020
Accepted: 2 February 2021
First Online: 18 February 2021
Competing interests
: Pr. Rossignol reports grants and personal fees from AstraZeneca, Bayer, CVRx, Fresenius, and Novartis, personal fees from Grunenthal, Servier, Stealth Peptides, Vifor Fresenius Medical Care Renal Pharma, Idorsia, NovoNordisk, Ablative Solutions, G3P, Corvidia, Relypsa. Pr Rossignol and Pr Zannad are the cofounder of CardioRenal. Pr Zannad has received fees for serving on the board of Boston Scientific; consulting fees from Novartis, Takeda, AstraZeneca, Boehringer-Ingelheim, GE Healthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson & Johnson, and Resmed; and speakers' fees from Pfizer and AstraZeneca. Pr Girerd reports personal fees from Novartis, Astra Zeneca and Boehringer. All other authors declare no competing interest related to this paper.